GLOW

Overview

GLOW is a popular peptide stack combining three synergistic compounds — GHK-Cu, BPC-157, and TB-500 — into a single protocol designed to support skin rejuvenation, collagen production, tissue repair, and anti-inflammatory recovery. Rather than a single molecule, GLOW represents a research-driven combination that leverages complementary mechanisms: GHK-Cu drives collagen synthesis and gene expression reprogramming, BPC-157 provides systemic anti-inflammatory and wound-healing support, and TB-500 promotes cell migration and organized tissue remodeling. The rationale is that targeting multiple regenerative pathways simultaneously may produce outcomes beyond what any single peptide achieves alone.

Mechanism of Action

1. GHK-Cu (Copper Tripeptide-1) — A naturally occurring copper-binding peptide whose levels decline from approximately 200 ng/mL at age 20 to 80 ng/mL by age 60. Stimulates collagen and elastin synthesis, promotes skin remodeling, attracts immune cells to damaged tissue, and modulates gene expression related to tissue repair. Research found GHK-Cu affects over 31% of human genes studied, with broad regenerative actions including resetting aged gene expression patterns toward younger profiles.
2. BPC-157 (Body Protection Compound) — Supports wound healing, promotes angiogenesis (new blood vessel formation), reduces systemic inflammation, and helps protect and repair the skin barrier. Its anti-inflammatory effects — including NF-κB pathway modulation — create an optimal healing environment for the other peptides in the stack.
3. TB-500 (Thymosin Beta-4 Fragment) — Promotes cell migration to damaged areas, supports organized collagen deposition, and reduces fibrosis in tissue. Works systemically to support regeneration throughout the body. Its anti-fibrotic properties help ensure new tissue forms in an organized, functional pattern rather than as scar tissue.

Research Highlights

1. GHK-Cu shown to increase skin elasticity by 11.8% in 30 days in clinical research, with collagen production improved in 70% of women in a 12-week topical study.
2. GHK-Cu increased decorin production by 302% and glycosaminoglycan accumulation in skin fibroblasts — key structural molecules for skin firmness and hydration.
3. BPC-157 demonstrated significantly increased collagen, reticulin, and blood vessel formation in animal wound-healing models, with 40–50% acceleration of wound closure compared to controls.
4. TB-500 shows anti-fibrotic properties while promoting organized collagen deposition — reducing scar formation while supporting functional tissue regeneration.
5. All three peptides share complementary anti-inflammatory mechanisms, inhibiting NF-κB and related inflammatory pathways — creating a multi-targeted approach to reducing chronic inflammation that impairs skin quality and healing.

Observed Benefits in Research

1. Enhanced collagen and elastin synthesis through multiple complementary pathways
2. Accelerated wound healing and tissue repair with reduced scarring
3. Broad anti-inflammatory effects via NF-κB inhibition from all three components
4. Gene expression reprogramming toward younger, healthier tissue profiles (GHK-Cu)
5. Improved skin firmness, elasticity, and hydration markers
6. Organized collagen deposition with reduced fibrosis (TB-500)
7. Angiogenesis support for improved nutrient delivery to healing tissue (BPC-157)
8. Synergistic mechanism coverage — collagen synthesis, immune modulation, and cell migration

Typical Research Protocol

GLOW is commonly formulated at a 5:1:1 ratio — GHK-Cu (50 mg) : TB-500 (10 mg) : BPC-157 (10 mg) — either as a combined vial or as individual peptides dosed separately. Most research protocols include a break of at least 15 days between cycles. Administration is typically subcutaneous injection. As with all peptide protocols, reconstitution with bacteriostatic water is standard and proper storage (refrigerated, protected from light) is essential for peptide stability.

Research Limitations

(1) GLOW is a combination protocol — no clinical trials have studied this specific three-peptide stack as a unified treatment. Evidence is extrapolated from individual peptide research. (2) Most GHK-Cu clinical data comes from topical applications; injectable research is more limited. (3) BPC-157 and TB-500 evidence is primarily preclinical (animal models) with limited human trial data. (4) Optimal ratios and dosing schedules for the combined stack have not been established through controlled research. (5) None of the component peptides are FDA-approved for human therapeutic use. (6) Individual responses may vary and long-term safety data for the combination is not available.

Component Profiles

Read the full research profile for each component peptide in the GLOW stack:

References

1. PMC. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. 2015. https://pmc.ncbi.nlm.nih.gov/articles/PMC4508379/
2. PMC. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. 2018. https://pmc.ncbi.nlm.nih.gov/articles/PMC6073405/
3. EurekAlert. Epigenetic mechanisms activated by GHK-Cu increase skin collagen density in clinical trial. 2023. https://www.eurekalert.org/news-releases/990464
4. PMC. Stable Gastric Pentadecapeptide BPC 157: Novel Therapy in Gastrointestinal Tract. 2016. https://pmc.ncbi.nlm.nih.gov/articles/PMC5333585/
5. PMC. Thymosin Beta 4 Is an Endogenous Iron Chelator and Molecular Switch of Ferroptosis. 2023. https://pmc.ncbi.nlm.nih.gov/articles/PMC9916557/